

CURRICULUM VITAE

MIRAN KIM

Mailing Address: Liver Research Center, 55 Claverick St., Providence, RI, 02903

Telephone: 1-401-444-4493

Fax: 1-401-444-2939

Email: Miran_Kim@brown.edu

EDUCATION

B.Sc. Pusan National University, College of Pharmacy, Pusan, Korea
Pharmacology, Mar.1979 - Feb.1983 (Feb.1983)

M.Sc. Seoul National University, Seoul, Korea
Biochemistry, Mar.1987 – Feb.1989 (Feb.1989)

Ph.D. KAIST, Taejon, Korea
Biological Science, Mar.1992 – Feb.1998 (Feb. 1998)

POSTGRADUATE TRAINING

Fellowship

Seoul National University, Seoul, Korea
Research Fellow, Jan.1998 – Dec. 1998

University of Sheffield, Institute of Molecular Physiology, Sheffield, UK
Senior Research Fellow, Jan. 1999 - Jan. 2003

HONORS AND AWARDS

AstraZeneca Research Fellowship (University of Sheffield, UK), 1999-2000

Wellcome Trust Research Fellowship (University of Sheffield, UK), 2001-2003

Developmental Research Award (Department of Medicine, Rhode Island Hospital),
2009-2011

ACADEMIC APPOINTMENTS

Research Assistant/Associate, Seoul National University, College of Medicine, Cancer
Research Center, Seoul, Korea. Feb. 1989 - Oct. 1995

Visiting scientist (Salk Institute, USA), 1995-1997

Assistant Professor of Medicine (Research) Warren Alpert Medical School of Brown
University, 2003 – present

HOSPITAL APPOINTMENTS

Assistant Director, COBRE Proteomics Core, Rhode Island Hospital, 2003 – Apr. 2004
Research Scientist, Liver Research Center, Rhode Island Hospital, 2003 – present

OTHER APPOINTMENTS

EDITORIAL BOARD

1. Cancer letters
2. World Journal of Gastroenterology

EDITORIAL CONSULTANT

1. Cancer Research
2. Oncogene
3. PLoS ONE
4. Molecular Cancer Research
5. Liver International
6. Cancer Letters
7. Journal of Cellular Biochemistry
8. Molecular Medicine
9. International Journal of Cancer
10. Medical Oncology
11. European Journal of Cancer
12. Cancer Cell International

MEMBERSHIP IN PROFESSIONAL SOCIETY

Regular member (2001-present), Biophysical Society, Bethesda, MD

Regular member (2005-present), New England Biomedical Society, Boston, MA

Active member (2008- present), American Association for Cancer Research, Philadelphia, PA

Regular member (2008-present), International Liver Cancer Association, Brussels, Belgium

PUBLICATIONS LIST

ORIGINAL PUBLICATIONS IN PEER-REVIEWED JOURNALS

1. Park S, **Kim M**, Kye K, and Kim NK. Demonstration of type 1 plasminogen activator inhibitor and its receptor on human platelet membrane. *Kor J Hematol* 27:47-53 (1992)
2. Kim JS, Kang JK, Chang HC, Lee M, Kim GS, Lee DK, Kim ST, **Kim M** and Park S. The thrombolytic effect of lumbrokinase is not as potent as urokinase in a rabbit cerebral embolism model. *J Kor Med Sci* 8:117-120 (1993)
3. Ryu GH, Park S, **Kim M**, Kim YH, and Min B. Antithrombogenicity of lumbrokinase-immobilized polyurethane. *J Biomed Mater Res* 28:1069-1077 (1994)
4. Baick SH, Hwang SG, Oh D, Kim CJ, **Kim M**, Lee JT and Park S. Urokinase type plasminogen activator (uPA) in stomach cancer. *Kor J Hemostas Thromb* 1:45-55 (1994)
5. Han JH, Park WS, Cho Y, Han YS, Han CW, **Kim M**, Kye KC, Lee HB, Byun JH, Park S and Lee M. Thrombolytic effect of lumbrokinase in thrombolytic model of ICR rat. *Kor J Hemostas Thromb* 1:149-154 (1994)
6. Park WS, Cho YS, Han CW, Lee GR, Byun JH, **Kim M**, Lee HB, Oh D, and Park S. Measurement of tissue-type plasminogen activator (t-PA) activity in human acidified plasma. *Kor J Hemostas Thromb* 1:193-198 (1994)
7. Ryu GH, Han DK, Park S, **Kim M**, Kim YH, and Min B. Surface characteristics and properties of lumbrokinase immobilized polyurethane. *J Biomed Mater Res* 29:403-409 (1995)
8. Bae HY, **Kim M**, Kee HS, Park S, KW Choe and. Expression of tissue factor and type I plasminogen activator inhibitor in cultured endothelial cells on *Rickettsia tsutsugamushi* infection. *Infection* 27:333-340 (1996)
9. Han CW, Lee JS, Park WS, Cho YS, Lee HB, Byun JH, **Kim M**, Oh D and Park S. Changes in plasminogen activator inhibitor-1 activities in pressure ulcer patients. *Kor J Hamatol* 31:73-79 (1996)
10. Park S, **Kim M**, Ryu GH, Lee HB, and Lee M. Characterization of biochemical properties and proteolytic activities of lumbrokinase extracted from *Lumbricus Rubellus*. *Kor J Hemostas Thromb* 3(2):105-113 (1996)
11. Park S, **Kim M**, and Lee JH. Expression of plasminogen activator and plasminogen activator inhibitor genes in leukemic cells. *Kor J Hemostas Thromb* 3(2):137-144 (1996)
12. Jeong H, **Kim M**, Lee J, Park S and Yoo OJ. A 5-nucleotide insertion in the antithrombin gene causing a quantitative antithrombin deficiency. *Thromb Haemost* 77(1): 212-213 (1997)
13. **Kim M**, Yoo OJ, and Choe S. Molecular assembly of the extracellular domain of P2X₂, an ATP gated ion channel. *Biochem Biophys Res Comm* 240:618-622 (1997)
14. Lee HB, Park SS, **Kim M**, Oh D, Kim CS, and Park S. High-dose busulfan, cyclophosphamide administration or total body irradiation stimulates collagen synthesis in rat liver within 24 hours. *Kor J Hemostas Thromb* 5(2):161-169 (1998)

15. **Kim M**, Spelta V, Sim J, North RA, and Surprenant A. Differential assembly of rat purinergic P2X7 receptor in immune cells of the brain and periphery. *J Biol Chem* 276:23262-23267 (2001)
16. **Kim M**, Jiang L-H, Wilson HL, North RA, and Surprenant A. Proteomic and functional evidence for a P2X7 receptor signalling complex. *EMBO Journal* 20(22):6347-6358 (2001)
17. Bo X, Jiang L-H, Wilson HL, **Kim M**, Burnstock G, Surprenant A, and North RA. Pharmacological and biophysical properties of the human P2X5 receptor. *Mol Pharmacol* 63(6):1407-1416 (2003)
18. Bo X, **Kim M**, Nori SL, Shoepfer R, Burnstock G, and North RA. Tissue distribution of P2X4 receptors studied with an ectodomain antibody. *Cell Tissue Res* 313:159-165 (2003)
19. Jiang L-H, **Kim M**, Young MT, Bo X, Surprenant A, and North RA. Subunit arrangement in P2X receptors. *J Neurosci* 26:8903-8910 (2003)
20. Adinolfi E, **Kim M**, Spelta V, Di Virgilio F, and Surprenant A. Tyrosine phosphorylation of Hsp90 within the P2X₇ receptor complex negatively regulates P2X₇ receptors. *J Biol Chem* 278:37344-37351 (2003)
21. Merle P, de la Monte S, **Kim M**, Herrmann M, Tanaka S, von den Bussche A, Kew MC, Trepo C, and Wands JR. Functional consequences of Frizzled-7 receptor over-expression in human hepatocellular carcinoma. *Gastroenterology* 127:1110-1122 (2004)
22. Merle P, **Kim M**, Herrmann M, Gupte A, Lefrancois L, Califano S, Trepo C, Tanaka S, Vitvitski L, de la Monte S, and Wands JR. Oncogenic role of the Frizzled-7/ β -catenin pathway in hepatocellular carcinoma. *J Hepatology* 43:854-862 (2005)
23. Lee HC, **Kim M**, and Wands JR. Wnt/frizzled signaling in hepatocellular carcinoma. *Frontiers in Bioscience* 11:1901-1915 (2006)
24. Lee HC, Tian B, Sedivy J, Wands JR, and **Kim M**. Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells. *Gastroenterology* 131:1208-1217 (2006)
25. **Kim M**, Lee HC, Tsedensodnom O, Hartley R, Lim Y-S, Yu E, Merle P, Wands JR. Functional interaction between Wnt3 and Frizzled-7 leads to activation of Wnt3/ β -catenin pathway in hepatocellular carcinoma cells. *J Hepatology* 48(5):780-791 (2008)
26. Bengochea A, de Souza MM, Lefrancois L, LeRoux E, Beseme S, Chemin I, **Kim M**, Wands JR, Trepo C, Hainaut P, Scoazec J-Y, Vitvitski L, Merle P. Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma. *Br J Cancer* 99:143-150 (2008)
27. Toyama T, Lee HC, Koga H, Wands JR, **Kim M**. Noncanonical Wnt11 inhibits hepatocellular carcinoma cell proliferation and migration. *Mol Cancer Res* 8(2):254-265 (2010)
28. Nambotin SB, Lefrancois L, Sainsily X, Berthillon P, **Kim M**, Wands JR, Chevallier M, Jalinet P, Scoazec J-Y, Trepo C, Zoulim F, and Merle P. Pharmacological

inhibition of frizzled-7 displays anti-tumor properties in hepatocellular carcinoma. *J Hepatol* 54(2):288-299 (2011)

29. Walker EJ, Rosenberg SA, Wands JR, and **Kim M**. The Role of Raf Kinase Inhibitor Protein in Hepatocellular Carcinoma. *Immunopathol Dis & Ther* 2(2):195-204 (2011)
30. Tsedensodnom O, Koga H, Rosenberg SA, Nambotin SB, Carrol JJ, Wands JR, and **Kim M**. Identification of T-cell factor-4 isoforms that contribute to the malignant phenotype of hepatocellular carcinoma cells. *Exp Cell Res* 317:920-931 (2011)
31. Nambotin SB, Wands JR, and **Kim M**. Promising treatment approaches and targets for hepatocellular carcinoma: Points of therapeutic intervention along the Wnt signaling pathway. *Anticancer Agents Med Chem* 11(6):549-559 (2011)
32. Koga H, Tsedensodnom O, Tomimaru Y, Walker EJ, Lee HC, Kim KM, Yano H, Wands JR, and **Kim M**. Loss of the SxxSS motif in a human T-cell factor-4 isoform confers hypoxia resistance to liver cancer: an oncogenic switch in Wnt signaling. *PLoS ONE* 7:e39981 (2012)
33. Nambotin SB, Tomimaru Y, Merle P, Wands JR, and **Kim M**. Functional consequences of WNT3/Frizzled7 mediated signaling in non-transformed hepatic cells. *Oncogenesis* 1:e31 (2012)
34. Tomimaru Y, Koga H, Shin TH, Xu CQ, Wands JR, and **Kim M**. The SxxSS motif of T-cell Factor-4 isoforms modulates Wnt/beta-catenin signal activation in hepatocellular carcinoma cells. *Cancer Lett* 336 (2):359-369 (2013)
35. Tomimaru Y, Koga H, Yano H, de la Monte S, Wands JR, and **Kim M**. Up-regulation of TCF-4 isoform-responsive target genes in hepatocellular carcinoma. *Liver Int* 33 (7):1100-1112 (2013)
36. Pez F, Lopez A, **Kim M**, Wands JR, Fromentel CC, and Merle P. Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs. *J Hepatol* S0168-8278 (13) 445-5 (2013)
37. Tomimaru Y, Xu CQ, Nambotin SB, Wands JR, and **Kim M**. Loss of exon 4 in a human T-cell factor-4 isoform promotes hepatic tumorigenesis. *Liver Int* 33 (10):1536-1548 (2013)

EDITORIAL

1. Wands JR and **Kim M**. WNT/ β -catenin signaling and hepatocellular carcinoma. *Hepatology* In press (2014)

BOOKS AND BOOK CHAPTERS

1. **Kim M** and Wands JR. Insulin pathway. In *Signaling Pathways in Liver Diseases*, J-F Dufour, P-A Clavien, Eds. (Heidelberg, Springer-Verlag GmbH & Co.), Chap 9.105-113 (2005)

2. **Kim M** and Wands JR. Insulin pathway. In *Signaling Pathways in Liver Diseases*, J-F Dufour, P-A Clavien, 2nd ed. (Heidelberg, Springer-Verlag GmbH & Co.), Chap 15.229-241 (2010)
3. Wands JR, and **Kim M**. Signaling pathways in viral related pre-neoplastic liver disease and hepatocellular carcinoma. In: *Molecular Genetics of Liver Neoplasia*. Wang, Grisham and Thorgeirsson, Eds. (New York, Springer Scientific), Chap 6. 103-127 (2011)

PATENT

1. Park S, Yun H, **Kim M**, Lee HB. Novel fibrinolytic enzymes and process for the purification thereof. KR0151825B1, 1998.
2. Park S, Yun H, **Kim M**, Lee HB. Novel fibrinolytic enzymes and purification method thereof. KR0215647B1, 1999.
3. Wands JR and **Kim M**. Wnt proteins and detection and treatment of cancer. US 8158761, 2012.
4. **Kim M**, Wands JR, Beseme S. Biomarkers for the treatment of hepatocellular carcinoma US 20130183674 A1, WO 2013106686 A1, 2013.

PRESENTATIONS AT NATIONAL AND INTERNATIONAL MEETINGS

1. **Kim M**, Jiang L-H, Wilson HL, North RA, and Surprenant A. Proteomics and functional evidence for a P2X7 receptor signalling complex. *Ann Biophysics Meeting*. (San Francisco, CA), Feb. 2002
2. Bo X, **Kim M**, Nori SL, Spelta V, Schoepfer V, Burnstock G, Surprenant A, and North RA. Co-immunoprecipitation of P2X receptor subunits from rat tissues. *Ann Neuroscience Meeting*. (Orlando, FL, USA), Nov. 2002
3. Merle P, de la Monte S, Herrmann M, Tanaka S, **Kim M**, Trepo C, and Wands JR. Functional consequences of frizzled-7 receptor over-expression in human hepatocellular carcinoma. *AASLD* (Boston, MA), Oct. 2003
4. Tian B, Lee HC, Sedivy J, Wands JR, and **Kim M**. Raf kinase inhibitor protein plays a central role in cell proliferation and migration in human hepatocellular carcinoma. *AASLD* (Boston, MA), Oct. 2005
5. Tsedensodnom O, Wands JR, and **Kim M**. Identification and characterization of transcription factor TCF-4 isoforms in human hepatocellular carcinoma. *AASLD* (Boston, MA, USA), Oct. 2006
6. Toyama T, Lee HC, Wands JR, and **Kim M**. Wnt11 inhibits the canonical Wnt pathway through the activation of non-canonical signaling in human hepatocellular carcinoma cells. *AASLD* (Boston, MA, USA), Oct. 2006
7. **Kim M**, Lee HC, Tsedensodnom O, and Wands JR. Activation of the b-catenin pathway in human hepatocellular carcinoma is mediated by a Wnt3 and Frizzled-7

receptor interaction. *Wnt signaling in development and disease*. (Berlin, Germany), Sep. 2007

8. Toyama T, Lee HC, Wands JR, and **Kim M**. Wnt11 inhibits the canonical Wnt pathway through the PKC-mediated β -catenin phosphorylation in human hepatoma cells. *AASLD* (Boston, MA, USA), Nov. 2007
9. Toyama T, Lee HC, Wands JR, and **M Kim**. Loss of Noncanonical Wnt11 Signaling Promotes Hepatocellular Carcinoma Cell Proliferation and Migration. *ILCA* (Chicago, IL, USA), Sep. 2008
10. Toyama T, Lee HC, Wands JR, and **M Kim**. Noncanonical Wnt11 signaling inhibits hepatocellular carcinoma cell proliferation and migration. *AASLD* (San Francisco, CA, USA), Oct. 2008
11. Beseme S, Sainsily X, Lefrancois L, **Kim M**, Wands JR, Fujii N, Jalinol P, Trepo C, Vitvitski L, Zouli F, Merle P. Small protein-mediated inhibition of frizzled-7 displays antitumor properties in hepatocellular carcinoma. *AASLD* (Boston, MA, USA), Nov. 2009
12. Tsedensodnom O, Koga H, Rosenberg SA, Carrol JJ, Wands JR, and **Kim M**. Identification of T-cell factor-4 isoforms that contribute to the malignant phenotype of hepatocellular carcinoma cells. *AASLD* (Boston, MA, USA), Nov. 2009
13. Koga H, Walker EJ, Tsedensodnom O, Nakashima O, Yano H, Wands JR, and **Kim M**. A T-cell factor-4 isoform promotes an aggressive hepatocellular carcinoma (HCC) phenotype involving hypoxia-inducible factor-2 α . *AASLD* (Boston, MA, USA), Oct. 2010
14. Koga H, Walker EJ, Tsedensodnom O, Wands JR, and **Kim M**. Tumor-initiating Potential of T-cell Factor-4 Variants derived from Human Hepatocellular Carcinoma. *ILCA* (Montreal, QC, Canada), Sep. 2010
15. Tsedensodnom O, Koga H, Wands JR, and **Kim M**. Characterization and function of unique T-cell factor-4 isoforms that alter the phenotype of hepatocellular carcinoma. *AACR* (Washington DC, USA), Apr. 2010
16. Koga H, Walker EJ, Tsedensodnom O, Wands JR, and **Kim M**. Preferential ubiquitination of hypoxia-inducible factors depends on the SxxSS motif in human T-cell factor-4 isoforms derived from hepatocellular carcinoma. *AACR* (Orlando, FL, USA), Apr. 2011
17. Koga H, Walker EJ, Tsedensodnom O, Wands JR, and **Kim M**. A T-cell factor-4 motif regulates the phenotype of hepatocellular carcinoma cells. *AACR* (Orlando, FL, USA), Apr. 2011
18. Tsedensodnom O, Koga H, Wands JR, and **Kim M**. Expression profile of fourteen splice-variants of T-cell factor-4 transcription factor of Wnt signaling in human HBV- and HCV-related HCC tissues. *AASLD* (San Francisco, CA, USA), Nov. 2011
19. Chung W, Longato L, **Kim M**, de la Monte S, and Wands JR. Upregulation of aspartate b-hydroxylase (ASPH) is a key event in the pathogenesis of hepatocellular carcinoma. *AASLD* (San Francisco, CA, USA), Nov. 2011

20. Tomimaru Y, Wands JR, and **Kim M**. Regulation of the Wnt/ β -catenin pathway in hepatocellular carcinoma cells by TCF-4 isoforms. *AASLD* (Boston, MA, USA), Nov. 2012
21. Tomimaru Y, Koga H, Wands JR, and **Kim M**. Identification of TCF-4 isoform regulated in hepatocellular carcinoma. *AASLD* (Boston, MA, USA), Nov. 2012
22. Nambotin SB, Tomimaru Y, Merle P, Wands JR, and **Kim M**. Functional consequences of Wnt3/Fzd7 mediated signaling in non-transformed hepatocyte derived cell lines. *AASLD* (Boston, MA, USA), Nov. 2012
23. Xu CQ, Tomimaru Y, Nambotin SB, Wands JR, and **Kim M**. Regulatory role of exon4 of TCF-4C and D isoforms in the development of hepatocellular carcinoma. *AASLD* (Boston, MA, USA), Nov. 2012
24. Nambotin SB, Tsedensodnom O, Gandhi AK, Wands JR, and **Kim M**. Effect of lenalidomide on TCF-4J isoform expression in poorly differentiated HCC cell lines. *AASLD* (Boston, MA, USA), Nov. 2012
25. Koga H, **Kim M**, Shin T-H, Tomimaru Y, Yano H, Ueno T, Torimura T, Wands JR, and Sata M. Drug resistance as a function of human T-cell factor-4 isoform expression in hepatocellular carcinoma cells. *AASLD* (Boston, MA, USA), Nov. 2012
26. Chung W, de la Monte S, **Kim M**, and Wands JR. Activation of interacting signal transduction pathways in an HBV-related double transgenic murine model of HCC. *AASLD* (Washington DC, USA), Nov. 2013
27. Koga H, **Kim M**, Nakamura A, Yano H, Ueno T, Nakamura T, Ueno T, Torimura T, Wands JR, and Sata M. T-cell factor-4 isoforms directly regulate Bcl-xL expression in human hepatocellular carcinoma (HCC) cells. *AASLD* (Washington DC, USA), Nov. 2013
28. Xu CQ, de la Monte SM, Wands JR, and **Kim M**. Chronic ethanol-induced impairment in Wnt/ β -catenin signaling is attenuated by PPAR δ agonist. *AASLD* (Washington DC, USA), Nov. 2013

PRESENTATIONS AT OTHER MEETING

1. Kim M, Jiang L-H, Wilson HL, North RA and Surprenant A. A P2X₇ receptor complex. *Ecto-ATPase Meeting*. (Woodhole, MA), Sep. 2002.
2. Adinolfi E, **Kim M**, Di Virgilio F, North RA and Surprenant A. The P2X₇-Hsp90 relationship: a matter of tyrosine phosphorylation? *Ecto-ATPase Meeting*. (Woodhole, MA), Sep. 2002
3. Lee HC, Tsedensodnom O, Wands JR, and **Kim M**. Wnt3 is a ligand for Frizzled-7 receptor and increases cell migration in human hepatoma cells. *COBRE/INBRE symposium, Stem Cell & Cancer Therapeutics*. (Providence, RI), May 2006
4. **Kim M**, Lee HC, Tian B, Sedivy JM, and Wands JR. Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells. *Biannual IDeA Meeting*. (Washington DC, USA), July 2006

5. Lee HC, Tsedensodnom O, Wands JR, and **Kim M.** Wnt3 is a ligand for Frizzled-7 receptor and increases cell migration in human hepatoma cells. *Biannual IDeA Meeting.* (Washington DC, USA), July 2006
6. Tsedensodnom O, Lee HC, Hartley R, Wands JR, and **Kim M.** Activation of the Wnt3/b-catenin pathway is mediated by Frizzled-7 receptor in human hepatoma cells. *The traditional Wnt meeting.* (La Jolla, CA, USA), Jun. 2007
7. Tsedensodnom O, Wands JR, and **Kim M.** Identification of unique TCF-4 isoforms that exhibit repressive functional characteristics in hepatocellular carcinoma. *RI Research Alliance.* (Providence, RI, USA), Jun. 2008

INVITED PRESENTATIONS

1. A P2X7 signaling complex. College of Medicine, Pochon Cha University, Korea (Aug. 24th, 2001) Invited lecture
2. Proteomic approach to membrane proteins. University of Sheffield, Department of Biomedical Science (Feb. 4th, 2002) Lecture
3. P2X7 receptor in a brain: detection by Western blot. Hassop Meeting for P2X receptors, Hassop, UK (Oct. 15th, 2002) Invited lecture
4. Wnt signaling in hepatocellular carcinoma. University of Ulsan, Korea (Feb. 1st, 2007) Invited lecture
5. Alterations of signaling pathways in hepatocarcinogenesis. International Symposium on Digestive Disease, Asan Medical Center, Seoul, Korea (July 5th, 2008) Invited lecture
6. Wnt signaling in hepatocellular carcinoma. Seoul National University Hospital, Seoul, Korea (July 9th, 2008) Invited lecture
7. The Role of Raf Kinase Inhibitor Protein in Hepatocellular Carcinoma. International Workshop on Prognostic and Therapeutic Applications of RKIP in Cancer. UCLA, Los Angeles, CA (March 19th, 2010) Guest Speaker
8. T-cell factor-4 isoforms in hepatocellular carcinoma. Mount Sinai School of Medicine, New York, NY (May 30, 2012) Invited lecture
9. Wnt signaling in cancer. UIC, Chicago, IL (Jan. 24th, 2014) Guest Speaker

GRANTS (for past and present grants, provide amount of support)

Ongoing Research Support

1R21AA0205878 (PI: Kim, M) 07/15/2012-06/30/2014
 NIH/NIAAA
Role of Wnt signaling in chronic alcoholic liver disease
 Role: PI
 \$250,000

Sponsored Research Agreement (PI: Wands, JR) 11/01/2013-10/31/2015
 CELGENE CORP.
Development Of Biomarkers For Hepatocellular Carcinoma Responsiveness To Drugs
 Role: Investigator

\$150,000/year

Completed Research Support

5P20RR015578 (PI: Atwood W) 8/31/05-2/28/2010
Center for Cancer Signaling Networks
Role: PI, Sub-Project (Wnt signaling in hepatocellular carcinoma)
\$817,935

Developmental Research Award (PI, Kim M) 6/1/09-5/31/2011
Rhode Island Hospital
The role of T-Cell Factor-4 (TCF-4) splicing variants in hepatocellular carcinoma
Role: PI
\$70,000

1R21 CA133601 (PI: Sedivy JM) 8/1/09-7/31/2011
NIH/NCI
Raf Kinase Inhibitor Protein (RKIP): A new hepatocellular carcinoma tumor suppressor
Role: Co-investigator
\$35,316

Sponsored Research Agreement (PI: Wands, JR) 05/01/2012-06/30/2013
CELGENE CORP.
Development Of Biomarkers For Hepatocellular Carcinoma Responsiveness To Drugs
Role: Co-Investigator
\$160,000

TRAINEES

Post-Doctoral Fellows

Han Chu Lee, MD, PhD (2004 – 2006)
Bo Tian, MD, PhD (2004 – 2005)
Takashi Toyama, MD (2006 – 2008)
Hironori Koga, MD (2008 – 2010)
Tao Yan, MD, PhD (2010 – 2011)
Sarah Beseme, PhD (2010 – 2112)
Yoshito Tomimaru, MD, PhD (2010 – 2013)
Arihiro Aihara, MD, PhD (2012 - 2013)
Chiung-Kuei Huang, PhD (2013 - present)

Graduate Students

Tsedensodnom, Orkhontuya 2005-2010

Undergraduate Independent Research

Hartley, Rochelle R. 2005-2007
Rosenberg, Stephen A. 2006-2008
Rhee, Jenny 2007-2008
Shin, Tai Ho 2007-2009
Rana, Ahmed 2008-2009

Walker, Evan J.	2008-2010
Vu, John	2010-2011
Xu, Chelsea	2010-2012